Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluocinonide
Drug ID BADD_D00925
Description A topical glucocorticoid used in the treatment of eczema.
Indications and Usage A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status approved; investigational
ATC Code C05AA11; D07AC08
DrugBank ID DB01047
KEGG ID D00325
MeSH ID D005447
PubChem ID 9642
TTD Drug ID D03ZZK
NDC Product Code 0093-0263; 40032-095; 51672-1279; 51672-1353; 63629-2509; 71085-006; 51552-0056; 52128-176; 51672-1273; 59088-755; 63629-2337; 68071-2667; 68071-4619; 99207-525; 0168-0457; 47781-602; 53002-9202; 63629-2339; 68071-2541; 71085-004; 71205-092; 68462-505; 68788-8105; 71085-005; 0093-0264; 51672-1253; 63629-2338; 0713-0663; 40032-026; 50090-6309; 53002-9201; 68071-2200; 69238-1534; 70771-1375; 0168-0134; 50090-2419; 51862-494; 63629-2508; 69238-1271; 76420-530; 46439-8707; 49452-3161; 0093-0262; 45802-151; 51672-1264; 53002-9200; 63629-2510; 70700-146; 70771-1393; 0713-0664; 62991-2865; 43386-095; 50090-3277; 63187-033; 68071-2202; 70710-1284; 71428-001; 72578-087; 43386-026; 51672-1386; 68071-2808; 33342-320; 0168-0135; 47781-569; 51672-1254
UNII 2W4A77YPAN
Synonyms Fluocinonide | Fluocinolone Acetonide 21-Acetate | Acetonide 21-Acetate, Fluocinolone | Fluocinolone Acetonide 21 Acetate | Fluocinonide FAPG | FAPG, Fluocinonide | Fluocinolide | Lidex | Lidemol | Lyderm | Tiamol | Topsyne | Novoter | Topsym | Topsyn | Klariderm | Metosyn
Chemical Information
Molecular Formula C26H32F2O7
CAS Registry Number 356-12-7
SMILES CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CC(C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.0030.000293%
Acne23.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Atrophy08.03.04.001--Not Available
Cataract subcapsular06.06.01.002--Not Available
Condition aggravated08.01.03.0040.000427%Not Available
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.001--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis contact10.01.01.003; 23.03.04.004; 12.03.01.040--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug ineffective08.06.01.0060.002720%Not Available
Dry skin23.03.03.001--
Erythema23.03.06.001--Not Available
Eye irritation06.04.05.0030.000453%Not Available
Folliculitis23.11.04.003; 11.02.01.053--
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hepatocellular injury09.01.07.0080.000200%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypersensitivity10.01.03.003--
Hypertrichosis23.02.04.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Leukoderma23.05.02.001--Not Available
Miliaria23.02.03.014--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.000293%
The 1th Page    1 2    Next   Last    Total 2 Pages